Agha Z, Lofgren RP, VanRuiswyk JV, Layde PM Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use. Arch Intern Med. 2000 Nov 27;160(21):3252-7.
American Diabetes Association 2. Classification and Diagnosis of Diabetes. Diabetes Care. 2017 Jan;40(Suppl 1):S11-S24. Review.
Barnett PG An improved set of standards for finding cost for cost-effectiveness analysis. Med Care. 2009 Jul;47(7 Suppl 1):S82-8. doi: 10.1097/MLR.0b013e31819e1f3f. Review.
Barton NH, Etheridge AM, Véber A The infinitesimal model: Definition, derivation, and implications. Theor Popul Biol. 2017 Dec;118:50-73. doi: 10.1016/j.tpb.2017.06.001. Epub 2017 Jul 11. Review.
Boyle EA, Li YI, Pritchard JK An Expanded View of Complex Traits: From Polygenic to Omnigenic. Cell. 2017 Jun 15;169(7):1177-1186. doi: 10.1016/j.cell.2017.05.038. Review.
Brown DW Smoking prevalence among US veterans. J Gen Intern Med. 2010 Feb;25(2):147-9. doi: 10.1007/s11606-009-1160-0. Epub 2009 Nov 6.
Carroll PH, Mohler JL NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection. J Natl Compr Canc Netw. 2018 May;16(5S):620-623. doi: 10.6004/jnccn.2018.0036.
Chatterjee N, Shi J, García-Closas M Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nat Rev Genet. 2016 Jul;17(7):392-406. doi: 10.1038/nrg.2016.27. Epub 2016 May 3. Review.
Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C Effectiveness-implementation hybrid designs: combining elements of clinical effectiveness and implementation research to enhance public health impact. Med Care. 2012 Mar;50(3):217-26. doi: 10.1097/MLR.0b013e3182408812.
Feero WG, Manolio TA, Khoury MJ Translational research is a key to nongeneticist physicians' genomics education. Genet Med. 2014 Dec;16(12):871-3. doi: 10.1038/gim.2014.67. Epub 2014 May 29.
Freeman JV, Wang Y, Akar J, Desai N, Krumholz H National Trends in Atrial Fibrillation Hospitalization, Readmission, and Mortality for Medicare Beneficiaries, 1999-2013. Circulation. 2017 Mar 28;135(13):1227-1239. doi: 10.1161/CIRCULATIONAHA.116.022388. Epub 2017 Feb 1.
Gibson G Rare and common variants: twenty arguments. Nat Rev Genet. 2012 Jan 18;13(2):135-45. doi: 10.1038/nrg3118. Review.
Ginsburg GS, Phillips KA Precision Medicine: From Science To Value. Health Aff (Millwood). 2018 May;37(5):694-701. doi: 10.1377/hlthaff.2017.1624. Review.
Golan D, Lander ES, Rosset S Measuring missing heritability: inferring the contribution of common variants. Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):E5272-81. doi: 10.1073/pnas.1419064111. Epub 2014 Nov 24.
Greene J, Hibbard JH Why does patient activation matter? An examination of the relationships between patient activation and health-related outcomes. J Gen Intern Med. 2012 May;27(5):520-6. doi: 10.1007/s11606-011-1931-2.
Grosse SD Economic analyses of genetic tests in personalized medicine: clinical utility first, then cost utility. Genet Med. 2014 Mar;16(3):225-7. doi: 10.1038/gim.2013.158. Epub 2013 Oct 10.
Harvey L, Fowles JB, Xi M, Terry P When activation changes, what else changes? the relationship between change in patient activation measure (PAM) and employees' health status and health behaviors. Patient Educ Couns. 2012 Aug;88(2):338-43. doi: 10.1016/j.pec.2012.02.005. Epub 2012 Mar 27.
Hirth JM, Hatch SS, Lin YL, Giordano SH, Silva HC, Kuo YF Development and validation of algorithms to differentiate ductal carcinoma in situ from invasive breast cancer within administrative claims data. Cancer. 2018 Jul 1;124(13):2815-2823. doi: 10.1002/cncr.31393. Epub 2018 Apr 18. Retraction in: Cancer. 2019 Apr 1;125(7):1200.
Islami F, Moreira DM, Boffetta P, Freedland SJ A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol. 2014 Dec;66(6):1054-64. doi: 10.1016/j.eururo.2014.08.059. Epub 2014 Sep 18. Review.
Karlson EW, Boutin NT, Hoffnagle AG, Allen NL Building the Partners HealthCare Biobank at Partners Personalized Medicine: Informed Consent, Return of Research Results, Recruitment Lessons and Operational Considerations. J Pers Med. 2016 Jan 14;6(1). pii: E2. doi: 10.3390/jpm6010002.
Kazis LE, Selim A, Rogers W, Ren XS, Lee A, Miller DR Dissemination of methods and results from the veterans health study: final comments and implications for future monitoring strategies within and outside the veterans healthcare system. J Ambul Care Manage. 2006 Oct-Dec;29(4):310-9.
Khoury MJ, Janssens AC, Ransohoff DF How can polygenic inheritance be used in population screening for common diseases? Genet Med. 2013 Jun;15(6):437-43. doi: 10.1038/gim.2012.182. Epub 2013 Feb 14. Review.
Khurshid S, Keaney J, Ellinor PT, Lubitz SA A Simple and Portable Algorithm for Identifying Atrial Fibrillation in the Electronic Medical Record. Am J Cardiol. 2016 Jan 15;117(2):221-5. doi: 10.1016/j.amjcard.2015.10.031. Epub 2015 Nov 6.
Knowles JW, Ashley EA Cardiovascular disease: The rise of the genetic risk score. PLoS Med. 2018 Mar 30;15(3):e1002546. doi: 10.1371/journal.pmed.1002546. eCollection 2018 Mar.
Kullo IJ, Jouni H, Olson JE, Montori VM, Bailey KR Design of a randomized controlled trial of disclosing genomic risk of coronary heart disease: the Myocardial Infarction Genes (MI-GENES) study. BMC Med Genomics. 2015 Aug 15;8:51. doi: 10.1186/s12920-015-0122-0.
Larsson SC, Drca N, Wolk A Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis. J Am Coll Cardiol. 2014 Jul 22;64(3):281-9. doi: 10.1016/j.jacc.2014.03.048.
Lemke AA, Harris-Wai JN Stakeholder engagement in policy development: challenges and opportunities for human genomics. Genet Med. 2015 Dec;17(12):949-57. doi: 10.1038/gim.2015.8. Epub 2015 Mar 12.
Lu CY, Williams MS, Ginsburg GS, Toh S, Brown JS, Khoury MJ A proposed approach to accelerate evidence generation for genomic-based technologies in the context of a learning health system. Genet Med. 2018 Apr;20(4):390-396. doi: 10.1038/gim.2017.122. Epub 2017 Aug 10. Review.
Lu-Yao GL, McLerran D, Wasson J, Wennberg JE An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA. 1993 May 26;269(20):2633-6.
Moyer VA; U S. Preventive Services Task Force. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014 Feb 18;160(4):271-81.
Nazi KM, Woods SS MyHealtheVet PHR: a description of users and patient portal use. AMIA Annu Symp Proc. 2008 Nov 6:1182.
Roberts MC, Kennedy AE, Chambers DA, Khoury MJ The current state of implementation science in genomic medicine: opportunities for improvement. Genet Med. 2017 Aug;19(8):858-863. doi: 10.1038/gim.2016.210. Epub 2017 Jan 12. Review.
Selkirk CG, Weissman SM, Anderson A, Hulick PJ Physicians' preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. Genet Test Mol Biomarkers. 2013 Mar;17(3):219-25. doi: 10.1089/gtmb.2012.0165. Epub 2013 Feb 7.
Siegel R, Desantis C, Jemal A Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014 Mar-Apr;64(2):104-17. doi: 10.3322/caac.21220. Epub 2014 Mar 17.
Siu AL; U S Preventive Services Task Force Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2015 Dec 1;163(11):861-8. doi: 10.7326/M15-2345. Epub 2015 Oct 27.
Smith AD, Crippa A, Woodcock J, Brage S Physical activity and incident type 2 diabetes mellitus: a systematic review and dose-response meta-analysis of prospective cohort studies. Diabetologia. 2016 Dec;59(12):2527-2545. Epub 2016 Oct 17. Review.
Torkamani A, Wineinger NE, Topol EJ The personal and clinical utility of polygenic risk scores. Nat Rev Genet. 2018 Sep;19(9):581-590. doi: 10.1038/s41576-018-0018-x. Review.
Vassy JL, Chun S, Advani S, Ludin SA, Smith JG, Alligood EC Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review. Clin Pharmacol Ther. 2019 Aug;106(2):360-373. doi: 10.1002/cpt.1223. Epub 2018 Oct 18.
Vassy JL, Korf BR, Green RC How to know when physicians are ready for genomic medicine. Sci Transl Med. 2015 May 13;7(287):287fs19. doi: 10.1126/scitranslmed.aaa2401.
Warren M The approach to predictive medicine that is taking genomics research by storm. Nature. 2018 Oct;562(7726):181-183. doi: 10.1038/d41586-018-06956-3.
White AJ, DeRoo LA, Weinberg CR, Sandler DP Lifetime Alcohol Intake, Binge Drinking Behaviors, and Breast Cancer Risk. Am J Epidemiol. 2017 Sep 1;186(5):541-549. doi: 10.1093/aje/kwx118.
Williams BA, Honushefsky AM, Berger PB Temporal Trends in the Incidence, Prevalence, and Survival of Patients With Atrial Fibrillation From 2004 to 2016. Am J Cardiol. 2017 Dec 1;120(11):1961-1965. doi: 10.1016/j.amjcard.2017.08.014. Epub 2017 Aug 30.
Williams JK, Feero WG, Leonard DG, Coleman B Implementation science, genomic precision medicine, and improved health: A new path forward? Nurs Outlook. 2017 Jan - Feb;65(1):36-40. doi: 10.1016/j.outlook.2016.07.014. Epub 2016 Aug 20.
Wu RR, Myers RA, Hauser ER, Vorderstrasse A, Cho A, Ginsburg GS, Orlando LA Impact of Genetic Testing and Family Health History Based Risk Counseling on Behavior Change and Cognitive Precursors for Type 2 Diabetes. J Genet Couns. 2017 Feb;26(1):133-140. doi: 10.1007/s10897-016-9988-z. Epub 2016 Jun 14.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.